PMC4642731

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully

Seven of 10 kidney transplant recipients who attempted weaning from oral immunosuppression were successfully maintained rejection-free on belatacept monotherapy alone, with stable excellent graft func

Effect: improvement; 7/10 patients weaned to belatacept monotherapy successfully